0001193125-21-132687.txt : 20210427 0001193125-21-132687.hdr.sgml : 20210427 20210427073200 ACCESSION NUMBER: 0001193125-21-132687 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20210427 DATE AS OF CHANGE: 20210427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 21855881 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 DEFA14A 1 d24332ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to §240.14a-12

INOZYME PHARMA, INC.

(Name of registrant as specified in its charter)

 

(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing Party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


LOGO

P.O. BOX 8016, CARY, NC 27512-9903

  

Inozyme Pharma, Inc.

Important Notice Regarding the

Availability of Proxy Materials

for the

Stockholders Meeting to be held on

June 23, 2021

For Stockholders as of record on April 26, 2021

 

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

To view the proxy statement and annual report, and to register to attend the virtual annual meeting, go to: www.proxydocs.com/INZY.

 

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

 

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. We have chosen to use these procedures for our annual meeting.

 

                   

 

LOGO   

For a convenient way to VIEW proxy materials and
VOTE go to www.proxydocs.com/INZY

 

Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.

 

Proxy Materials Available to View or Receive: Proxy Statement and Annual Report

 

  LOGO
  

 

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 14, 2021.

 

To request paper materials, use one of the following methods.

 

LOGO

INTERNET

www.investorelections.com/INZY

   

LOGO

    TELEPHONE    

    (866) 648-8133    

    

LOGO

    * E-MAIL    

    paper@investorelections.com    

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

     * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located in the shaded box above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

 

 

Inozyme Pharma, Inc.

 

Meeting Type: Annual Meeting of Stockholders

For holders as of: April 26, 2021

Date: Wednesday, June 23, 2021

Time: 09:00 AM, Eastern Time

Place: Annual Meeting to be held live via Internet. Please visit

            www.proxydocs.com/INZY for more details.

 

In order to attend the meeting online and to vote your shares electronically during the meeting, you must register in advance at www.proxydocs.com/INZY prior to the registration deadline of June 21, 2021 at 5:00 PM, Eastern Time.


Inozyme Pharma, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE

FOR EACH OF THE NOMINEES IN

PROPOSAL 1 AND FOR PROPOSAL 2.

 

    

PROPOSAL

 

1.

To elect the three Class I directors named below to a 3-year term expiring at the 2024 annual meeting of stockholders.

1.01 Axel Bolte

1.02 Robert Hopfner

1.03 Edward Mathers

 

2.

To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021.

Note: To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

GRAPHIC 2 g243321a.jpg GRAPHIC begin 644 g243321a.jpg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g243321b.jpg GRAPHIC begin 644 g243321b.jpg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g243321c.jpg GRAPHIC begin 644 g243321c.jpg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end GRAPHIC 5 g243321d.jpg GRAPHIC begin 644 g243321d.jpg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g243321e.jpg GRAPHIC begin 644 g243321e.jpg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g243321f.jpg GRAPHIC begin 644 g243321f.jpg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end